Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Loss and Comprehensive Loss (Unaudited)

v3.24.3
Consolidated Statements of Loss and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
EXPENSES        
Research and development $ 7,609 $ 3,581 $ 15,521 $ 13,700
General and administrative 4,857 2,991 11,358 9,164
Total operating expenses 12,466 6,572 26,879 22,864
OTHER INCOME (EXPENSE)        
Interest income 673 262 1,874 617
Interest expense [note 7] (366) (781) (1,983) (2,066)
Change in fair value of contingent consideration [note 5 and note 6] (62)   (171)  
Loss on extinguishment of 2023 SVB convertible term loan [note 7] (283)   (283)  
Other expense (8) (17) (25) (26)
Total other expense (46) (536) (588) (1,475)
Net loss (12,512) (7,108) (27,467) (24,339)
OTHER COMPREHENSIVE LOSS        
Net unrealized loss on securities 82   71  
Total other comprehensive loss 82   71  
Comprehensive loss $ (12,430) $ (7,108) $ (27,396) $ (24,339)
Basic net loss per common share [note 8[d]] $ (0.36) $ (0.34) $ (0.88) $ (1.26)
Diluted net loss per common share [note 8[d]] $ (0.36) $ (0.34) $ (0.88) $ (1.26)
Weighted average shares used in computation of basic net loss per common share [note 8[d]] 34,355,050 21,127,281 31,251,997 19,376,316
Weighted average shares used in computation of diluted net loss per common share [note 8[d]] 34,355,050 21,127,281 31,251,997 19,376,316